Diagnostic Center | July 27, 2022
Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)